+91-9811715635
info@daedal-research.com
+91-9811715635
info@daedal-research.com
Price: US$ 800.00 | Pages : 58 | Publish Date : Nov 2016
Majority of biosimilars are in pipeline as most of the major biologics have either already expired or are about to lose their patent in the next two years which act as a major driving force for the biosimilar market. Four major biologics namely Humira, Enbrel, Remicade and Infliximab patents are set...
Detail...
Price: US$ 800.00 | Pages : 54 | Publish Date : Nov 2016
Tardive dyskinesia has many different treatments, including vitamin E, benzodiazepines, levodopa, reserpine, botullinum toxin, tetrabenazine, dopamine-depleting agents, and calcium channel blockers. Along with these, two new treatments are in the pipeline: Valbenazine and SD-809....
Detail...
Price: US$ 900.00 | Pages : 72 | Publish Date : Oct 2016
The global PARP inhibitor market has flourished since 2015 as in late 2014, the first PARP inhibitor product was launched and projections are made that the market would rise in the next five years i.e. 2016-2020 tremendously. The market is spread across the globe with the United States and Europe do...
Detail...
Price: US$ 900.00 | Pages : 76 | Publish Date : Oct 2016
The biopreservation market by product type has the following sub segments: equipment market, media market and laboratory information management system (LIMS). The biopreservation market by application can be classified into: biobanking, regenerative medicine and drug discovery....
Detail...
Price: US$ 800.00 | Pages : 37 | Publish Date : Oct 2016
Cancer is diagnosed using various tools, which confirm the presence of tumour, and the rate of its growth within the body. Cancer diagnosis can be segmented into: imaging testing, endoscopy, biopsy and tumour marker. Each segment can be sub segmented....
Detail...
Copyright © 2019 Daedal Research.
Privacy Policy |
Refund Policy |
Terms and Conditions
